There is increasing recognition of the important role of patient-focused drug development (PFDD) in oncology. Reflecting this, the FDA?S oncology center of excellence's (OCE) PFDD program identifies…

Ended Definitive Contract Awarded Last action

Contract number
75F40121C00162
Awardee
Awarding agency
Obligated
$347,762

Award facts

Opportunity
Contract value 100% obligated
$347,762.49 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Basic Research
Pricing
Cost No Fee
Place of performance
Silver Spring, MD 20993, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Close Out P00005 -$2,591
Other Administrative Action P00004 · The purpose of this modification is to extend the period of performance end date to december 30, 2024. $0
Other Administrative Action P00003 $0
Other Administrative Action P00002 $0
Other Administrative Action P00001 $0
Original award $350,353

About this award

Written by GovTribe AI ·

This federal contract award, valued at $347,762.49, was issued by the Food and Drug Administration (FDA) to Northwestern University to conduct research and development supporting the FDA's Oncology Center of Excellence's Patient-Focused Drug Development (PFDD) program. The contract is a definitive, cost-no-fee contract with an ultimate completion date of December 30, 2024.

The original solicitation was a Broad Agency Announcement (BAA) seeking proposals across eight areas of regulatory science to modernize various FDA functions. This award under the BAA does not have a set-aside designation. Northwestern University is the prime contractor, with subcontractors including the University of Alabama at Birmingham, Trustees of Boston University, and the University of Tasmania. The research aims to advance scientific knowledge and measurement of patient experiences in oncology, aligning with the FDA's efforts to incorporate patient perspectives into the drug development process.

Description

As the agency reported it.

There is increasing recognition of the important role of patient-focused drug development (PFDD) in oncology. Reflecting this, the FDA?S oncology center of excellence's (OCE) PFDD program identifies research into measurement of patient experi

Subawards

Subcontractor Amount Awarded
University Of Alabama At Birmingham THE PURPOSE OF THIS MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE END DATE TO DECEMBER 30, 2024. The American Lung Association (ALA) Lung Health Cohort $40,061
Trustees Of Boston University THE PURPOSE OF THIS MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE END DATE TO DECEMBER 30, 2024. The American Lung Association (ALA) Lung Health Cohort $45,985
University Of Tasmania THE PURPOSE OF THIS MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE END DATE TO DECEMBER 30, 2024. Evaluation of a Global Item for Side Effect Bother $25,905

Quick answers

Who was awarded contract 75F40121C00162?

75F40121C00162 was awarded to Northwestern University by Food and Drug Administration (Department of Health and Human Services) on September 27, 2021.

How much is contract 75F40121C00162 worth?

The government has obligated $347,762 on 75F40121C00162.

Was contract 75F40121C00162 competed?

The extent of competition for 75F40121C00162 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login